aviscera bioscience  
AVISCERA BIOSCIENCE
 
line decor
  HOME  ::  
line decor
   
 
CD95 (Soluble)/Fas ELISA Kit
A biomarker for cardiovascular diseases

Longitudinal trends in sFas, a biomarker of apoptosis, after an acute coronary syndrome: Clues to the pathogenesis underlying adverse events on follow-up

Cardinal H et al. Int J Cardiol. 2014 Mar 22. pii: S0167-5273(14)00575-0

Usefulness of soluble fas levels for improving diagnostic accuracy and prognosis for acute coronary syndromes

Although both inflammation and apoptosis occur in acute coronary syndromes (ACSs), previous studies have not tested the diagnostic and prognostic utility of an approach that measures circulating markers of these pathways. The aim of the present study was to assess whether measuring soluble Fas (sFas) and high-sensitivity C-reactive protein (hs-CRP), as markers of apoptosis and inflammation, improve ACS diagnostic and prognostic accuracy. In a prospective cohort of consecutive subjects admitted to the hospital for suspicion of ACS, we measured sFas, hs-CRP, and troponin T in those who had a final noncardiac chest pain diagnosis (n = 100), those who had an ACS diagnosis and experienced (n = 218) or did not experience (n = 170) recurrent cardiac events during 1 year of follow-up. sFas was strongly and independently associated with a discharge diagnosis of an ACS versus noncardiac chest pain during the index hospitalization (odds ratio 16.16 for the second vs first tertile, 95% confidence interval [CI] 7.07 to 36.91; and odds ratio 25.40 for the third vs first tertile, 95% CI 9.38 to 68.75). However, hs-CRP was not. sFas significantly improved the diagnostic accuracy for ACSs (C statistic increased from 0.85 to 0.93, difference +0.08, 95% CI for the difference 0.05 to 0.11). The sFas levels were high and did not vary with time in the subjects having early versus late measurements (beta 0.00 ln pg/ml/hour, 95% CI -0.01 to 0.01). In contrast, troponin increased with time since the beginning of the symptoms (beta 0.07 ln microg/L/hour, 95% CI 0.04 to 0.10). Baseline sFas and hs-CRP did not predict recurrent cardiac events. In conclusion, our results suggest that in suspected ACS cases, sFas, but not hs-CRP, helps to improve the diagnostic accuracy and timeliness over and above standard diagnostic criteria.
Cardinal H et al. Am J Cardiol. 2010 Mar 15;105(6):797-803.
human sloble Fas CD95 elisa kit from aviscera bioscience Human Soluble Fas/CD95 ELISA Kit
Code No.: SK00890-01
Size: 96 T
Price: $390.00 USD
Standard range:4.7-300 pg/ml
Sensitivity: 2 pg/ml
Intra-CV: 4-6%
Inter-CV: 8-10%
Sample Type: serum, plasma
Protocol: PDF

 

Name
Code
Size
Price ($)
Fas/CD95/APO-1 (SOLUBLE) (HUMAN) ELISA KIT
96 T
39000
Soluble CD95/Fas (Human) rec. (293 cells derived)
00890-01-10
10 ug
90.00
Anti Soluble CD95/Fas (Human) IgG
00890-02-100
100 ug
290.00